Jean Franchi
Director of Finance/CFO at DISC MEDICINE, INC.
Net worth: 3 M $ as of 2024-03-30
Profile
Jean M.
Franchi currently works at Biodesix, Inc., as Independent Director from 2020, Flamingo Therapeutics BV, as Director, VectorY BV, as Director, Dynacure SA, as Member-Supervisory Board from 2021, and Disc Medicine, Inc., as Chief Financial Officer & Treasurer from 2024.
Ms. Franchi also formerly worked at International Institute of New England, Inc., as Director from 2016 to 2019, Biophytis SA, as Independent Director from 2017 to 2021, Visioneering Technologies, Inc., as Independent Non-Executive Director from 2017 to 2022, Wyeth LLC, as Manager-Sales Analysis, Genzyme Corp., as Controller & Senior VP-Corporate Finance from 1995 to 2011, Merrimack Pharmaceuticals, Inc., as CFO, Treasurer & Principal Accounting Officer from 2017 to 2019, bioMérieux, Inc., as Senior Financial Analyst, Sanofi SA, as Senior Vice President-Business Unit Finance, Good Start Genetics, Inc., as Chief Financial Officer from 2012 to 2015, Dimension Therapeutics, Inc., as Chief Financial Officer, Secretary & Treasurer from 2015 to 2017, and Replimune Group, Inc., as Chief Financial Officer, Secretary & Treasurer from 2019 to 2023.
Ms. Franchi received her undergraduate degree in 1992 from Hofstra University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DISC MEDICINE, INC.
0.15% | 2024-02-06 | 36,666 ( 0.15% ) | 2 M $ | 2024-03-30 |
REPLIMUNE GROUP, INC.
0.03% | 2023-06-29 | 21,355 ( 0.03% ) | 174 470 $ | 2024-03-30 |
| 2020-06-03 | 1,196,500 ( 2.25% ) | 140 505 $ | 2024-03-30 | |
BIODESIX, INC.
0.08% | 2023-12-31 | 81,772 ( 0.08% ) | 116 934 $ | 2024-03-30 |
Jean Franchi active positions
| Companies | Position | Start |
|---|---|---|
| BIODESIX, INC. | Director/Board Member | 2020-03-31 |
| DISC MEDICINE, INC. | Director of Finance/CFO | 2024-02-06 |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Director/Board Member | - |
Flamingo Therapeutics BV
 Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Director/Board Member | - |
Dynacure SA
 Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Director/Board Member | 2021-01-20 |
Former positions of Jean Franchi
| Companies | Position | End |
|---|---|---|
| REPLIMUNE GROUP, INC. | Director of Finance/CFO | 2023-06-01 |
| VISIONEERING TECHNOLOGIES, INC. | Director/Board Member | 2022-12-18 |
| BIOPHYTIS S.A. | Director/Board Member | 2021-07-06 |
| MERRIMACK PHARMACEUTICALS, INC. | Director of Finance/CFO | 2019-06-27 |
| ░░░░░░░░░░░░░ ░░░░░░░░░ ░░ ░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Jean Franchi
| Hofstra University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| BIODESIX, INC. | Health Services |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| BIOPHYTIS S.A. | Health Technology |
| VISIONEERING TECHNOLOGIES, INC. | Electronic Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Private companies | 11 |
|---|---|
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
International Institute of New England, Inc.
 International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | Health Services |
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Health Technology |
| Sanofi SA | Health Technology |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Commercial Services |
| Disc Medicine, Inc. | |
Good Start Genetics, Inc.
 Good Start Genetics, Inc. Medical/Nursing ServicesHealth Services Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA. | Health Services |
- Stock Market
- Insiders
- Jean Franchi
